Microbial Biotechnology Laboratory, Life Sciences Division, Institute of Advanced Studies in Science and Technology, Guwahati, Assam, 781035, India.
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
Curr Microbiol. 2022 Sep 25;79(11):330. doi: 10.1007/s00284-022-03029-7.
An increasing number of bacterial pathogens are acquiring resistance to the commonly used antibiotics. This has spurred a global threat leading to a resistance era and has penetrated the consciousness of the common people and the clinicians alike. The delay in discovering new antibiotics has exacerbated the resistance problem, forcing researchers to focus on unconventional antimicrobial therapeutics that differ from conventional antibiotics. Alternative therapies have emerged in recent years, including antimicrobial peptides, phage therapy, efflux pump inhibitors, antibodies, and immunomodulatory agents, which have produced impressive results in both laboratory and in clinical trials. Additionally, ultra-narrow-spectrum therapeutics such as CRISPR-Cas system and peptide nucleic acids aided in the development of sequence-specific antimicrobials. Moreover, combinatorial therapies that combine these new approaches have been efficient enough to get approval for clinical use and have accelerated the discovery of novel combination approaches that enhance the performance of already in-use antibiotics. In this review, we provide an overview of these approaches along with studies that focus on the uncharted microbial territories that have been able to deliver some of the important new antibiotics of recent times. It is hoped that the information gathered in this article will provide an update on the current antibiotic resistance threat and encourage profound research.
越来越多的细菌病原体对常用抗生素产生了耐药性。这引发了一场全球性的威胁,导致了耐药时代的到来,引起了普通民众和临床医生的关注。新抗生素的发现滞后加剧了耐药问题,迫使研究人员专注于与传统抗生素不同的非传统抗菌治疗方法。近年来出现了替代疗法,包括抗菌肽、噬菌体治疗、外排泵抑制剂、抗体和免疫调节剂,这些疗法在实验室和临床试验中都取得了令人瞩目的效果。此外,超窄谱治疗方法,如 CRISPR-Cas 系统和肽核酸,有助于开发序列特异性抗菌药物。此外,这些新方法的组合疗法已经有效到足以获得临床使用的批准,并加速了发现新的组合方法,以提高现有抗生素的性能。在这篇综述中,我们概述了这些方法,并介绍了一些专注于未开发微生物领域的研究,这些领域已经能够提供一些最近的重要新型抗生素。希望本文收集的信息能为当前抗生素耐药性威胁提供最新情况,并鼓励开展深入研究。